Similar articles

• PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.

  Kearns JT, Holt SK, Wright JL, Lin DW, Lange PH, Gore JL. Kearns JT, et al. Cancer. 2018 Jul 1;124(13):2733-2739. doi: 10.1002/cncr.31337. Epub 2018 May 21. Cancer. 2018. PMID: 29781117
• Group now advises against routine PSA screening.

  Mitka M. Mitka M. JAMA. 2013 Jun 12;309(22):2316. doi: 10.1001/jama.2013.6922. JAMA. 2013. PMID: 23757064 No abstract available.
• Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening.

  Schröder FH. Schröder FH. N Engl J Med. 2011 Nov 24;365(21):1953-5. doi: 10.1056/NEJMp1112140. Epub 2011 Oct 26. N Engl J Med. 2011. PMID: 22029756 No abstract available.
• Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.

  Eapen RS, Herlemann A, Washington SL 3rd, Cooperberg MR. Eapen RS, et al. Curr Opin Urol. 2017 May;27(3):205-209. doi: 10.1097/MOU.0000000000000383. Curr Opin Urol. 2017. PMID: 28221220 Review.
• Prostate cancer screening.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2008 Nov 3;50(1298):85-6. Med Lett Drugs Ther. 2008. PMID: 18978703 Review. No abstract available.